Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

NIH Eyes Expansion Of US FDA Partnerships To Gene Therapy

Executive Summary

NIH Director Francis Collins describes evolution of existing collaborations and how the two agencies might facilitate development of gene therapy, such as by having a common template for regulatory review.

You may also be interested in...



NIH Partnership To Pick COVID-19 Therapeutics For Clinical Trials; Results Anticipated By Summer

NIH public-private partnership with FDA, CDC, BARDA and 16 biopharma companies to rank most promising therapeutics and vaccines to advance into clinical trials; candidates expected to be tested simultaneously under master protocol.

NIH Ends Gene Therapy Trial Reporting Requirements In Reg Streamlining Move

Trial protocols, annual reports, and adverse event reports on gene therapies will only go to US FDA under now-finalized amendments, a sign that the product category is maturing and can be regulated like other drugs and biologics.

NIH And 10 Biopharmas Hatch Plan To Accelerate And Improve Therapeutic Pathway Research

With $230 million from industry and NIH, the Accelerating Medicines Partnership seeks to hasten and improve the success rate for discovery of biomarkers and therapeutic pathways in Alzheimer’s, type 2 diabetes, rheumatoid arthritis and lupus.

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS141006

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel